Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status
Table 1
Patients’ characteristics at T0.
T0
Group 0 N = 29
Group 1 N = 19
Group 2 N = 21
value
Age
35.01 ± 10.57
32.47 ± 9.40
38.93 ± 7.14
0.092
Creatinine (mg/dL)
0.75 ± 0.14
0.76 ± 0.11
0.83 ± 0.10
0.060
eGFR (ml/min)
110.0 ± 25.26
107.60 ± 13.98
103.46 ± 22.42
0.580
Serum nitrogen (mg/dL)
5.17 ± 1.42
5.48 ± 1.19
5.26 ± 1.01
0.700
Serum uric acid (mmol/L)
0.32 ± 0.07
0.33 ± 0.06
0.37 ± 0.09
0.065
Serum sodium (mEq/L)
140.33 ± 3.23
141.33 ± 2.11
140.73 ± 2.32
0.458
Serum potassium (mEq/L)
4.56 ± 0.40
4.43 ± 0.29
4.58 ± 0.40
0.387
Total protein (g/dL)
7.67 ± 0.30
7.73 ± 0.44
7.63 ± 0.51
0.744
Serum albumin (g/dL)
4.51 ± 0.35
4.46 ± 0.25
4.42 ± 0.19
0.552
Serum fibrinogen (g/L)
3.31 ± 0.53
3.49 ± 0.74
3.33 ± 0.85
0.658
Serum transferrin (g/L)
2.83 ± 0.48
3.08 ± 0.60
2.80 ± 0.37
0.140
White blood cells ×10³ cells/µL
8.16 ± 3.23
7.34 ± 1.74
7.86 ± 2.08
0.558
HbA1c (%)
5.53 ± 0.45
5.86 ± 1.01
5.38 ± 0.51
0.074
CRP (µg/L)
4663.0 ± 9948.0
4435.55 ± 158.26
5400.0 ± 1096.0
0.883
NLR
2.39 ± 1.34
2.37 ± 1.08
2.15 ± 0.98
0.750
Neutrophils, ×10³
4345.0 ± 1657.09
4493.0 ± 1736.34
4696.0 ± 1740.20
0.773
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, A1c haemoglobin; N, number of patients; NLR, neutrophil-to-lymphocyte ratio. Data are shown as mean ± standard deviation or number (%). Group 0: CF patients on conservative therapy (controls); group 1: CF patients with CFTR modulator therapy; group 2: lung transplant recipient patients.
